EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Next-generation CDK inhibitors in HR+/HER2– breast cancer

Daria Seriak, Jun Yong Kim, Geoffrey I Shapiro, Antonio Giordano

Journal of Clinical Investigation · 2026

DOI: 10.1172/jci207631 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Clinical Investigation, 2026. Verfasst von Daria Seriak und 3 weiteren Autor:innen. Beteiligte Einrichtung: Dana-Farber Cancer Institute at Boston Medical Center, Brighton, Massachusetts, USA. Hauptthemen laut MEDLINE: Breast Neoplasms, Erb-b2 Receptor Tyrosine Kinases, Protein Kinase Inhibitors, Cyclin-Dependent Kinase 4. Die Arbeit nennt 108 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cell-cycle dysregulation is a central driver of breast cancer progression and a major therapeutic vulnerability, particularly in hormone receptor–positive/human epidermal growth factor receptor 2–negative (HR + /HER2 – ) disease. The clinical success of cyclin-dependent kinase (CDK) 4/6 inhibitors combined with endocrine therapy has transformed treatment paradigms and established cell-cycle targeting as a cornerstone of care. However, important challenges remain, including hematologic toxicity, incomplete and largely cytostatic responses, and the near-universal development of resistance. These limitations have highlighted the need for next-generation CDK-directed strategies capable of improving selectivity, extending disease control, and overcoming adaptive escape pathways. This Review examines the evolving landscape of CDK-targeted therapeutics in breast cancer, with particular emphasis on emerging CDK4-selective inhibitors, CDK2-directed approaches, and broader multi-CDK strategies. We discuss the biological rationale underpinning these agents, the mechanisms of resistance that have informed their development, and the clinical opportunities they may create across both advanced and early-stage settings. By refining target specificity and addressing resistance-associated cell-cycle rewiring, next-generation CDK inhibitors may reduce toxicity, enhance treatment durability, and enable more effective combination and sequencing strategies. Collectively, these advances promise to move breast cancer treatment beyond current CDK4/6 inhibition toward more precise, adaptable, and durable cell-cycle–directed therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsErb-b2 Receptor Tyrosine KinasesProtein Kinase InhibitorsCyclin-Dependent Kinase 4Cyclin-Dependent Kinase 6HumansFemaleAnimalsCyclin-Dependent Kinase 2Receptors, EstrogenReceptors, ProgesteroneDrug Resistance, Neoplasm

Substanzen

Erb-b2 Receptor Tyrosine KinasesProtein Kinase InhibitorsCyclin-Dependent Kinase 4ERBB2 protein, humanCyclin-Dependent Kinase 6CDK4 protein, humanCyclin-Dependent Kinase 2CDK6 protein, humanReceptors, EstrogenReceptors, Progesterone

Autor:innen und Institutionen

  • Dana-Farber Cancer Institute at Boston Medical Center, Brighton, Massachusetts, USA.
  • Department of Medicine, Boston University Chobanian & Avedisian School of Medicine, Boston, Massachusetts, USA.
  • Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
  • Department of Medicine, Brigham and Women's Hospital and Harvard Medical, School, Boston, Massachusetts, USA.

Zitieren

APA

Seriak, D., Kim, J. Y., Shapiro, G. I., & Giordano, A. (2026). Next-generation CDK inhibitors in HR+/HER2– breast cancer. Journal of Clinical Investigation. https://doi.org/10.1172/jci207631

Vancouver

Seriak D, Kim JY, Shapiro GI, Giordano A. Next-generation CDK inhibitors in HR+/HER2– breast cancer. Journal of Clinical Investigation. 2026. doi:10.1172/jci207631

BibTeX
@article{Seriak2026,
  author = {Seriak, Daria and Kim, Jun Yong and Shapiro, Geoffrey I and Giordano, Antonio},
  title = {Next-generation CDK inhibitors in HR+/HER2– breast cancer},
  journal = {Journal of Clinical Investigation},
  year = {2026},
  doi = {10.1172/jci207631}
}
Kostenlos starten →